These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26093599)

  • 21. Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study.
    Fadai F; Mousavi B; Ashtari Z; Ali beigi N; Farhang S; Hashempour S; Shahhamzei N; Bathaie SZ
    Pharmacopsychiatry; 2014 Jul; 47(4-5):156-61. PubMed ID: 24955550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
    Carrizo E; Fernández V; Connell L; Sandia I; Prieto D; Mogollón J; Valbuena D; Fernández I; de Baptista EA; Baptista T
    Schizophr Res; 2009 Aug; 113(1):19-26. PubMed ID: 19515536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.
    Henderson DC; Fan X; Sharma B; Copeland PM; Borba CP; Freudenreich O; Cather C; Evins AE; Goff DC
    J Psychiatr Pract; 2009 Jul; 15(4):251-61. PubMed ID: 19625881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia.
    Wang CH; Li Y; Yang J; Su LY; Geng YG; Li H; Wang JK; Mu JL
    Schizophr Res; 2013 Mar; 144(1-3):129-35. PubMed ID: 23352776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.
    Modabbernia A; Heidari P; Soleimani R; Sobhani A; Roshan ZA; Taslimi S; Ashrafi M; Modabbernia MJ
    J Psychiatr Res; 2014 Jun; 53():133-40. PubMed ID: 24607293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.
    Kaushal J; Bhutani G; Gupta R
    Singapore Med J; 2012 Jul; 53(7):488-92. PubMed ID: 22815019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.
    Daly EJ; Kent JM; Janssens L; Newcomer JW; Hüsken G; De Boer P; Tritsmans L; Schmidt ME
    Ann Clin Psychiatry; 2013 Aug; 25(3):173-83. PubMed ID: 23926573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
    McDonnell DP; Kryzhanovskaya LA; Zhao F; Detke HC; Feldman PD
    Hum Psychopharmacol; 2011 Aug; 26(6):422-33. PubMed ID: 21823172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome.
    Asemi Z; Foroozanfard F; Hashemi T; Bahmani F; Jamilian M; Esmaillzadeh A
    Clin Nutr; 2015 Aug; 34(4):586-92. PubMed ID: 25300649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.
    Taveira TH; Wu WC; Tschibelu E; Borsook D; Simonson DC; Yamamoto R; Langleben DD; Swift R; Elman I
    J Psychopharmacol; 2014 Apr; 28(4):395-400. PubMed ID: 24218048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is Sitagliptin Effective for Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients? A Double-blind Placebo-controlled Clinical Trial.
    Moghimi Sarani E; Memari E; Anushiravani A; Mowla A
    J Clin Psychopharmacol; 2020; 40(5):487-490. PubMed ID: 32701903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls.
    Hahn MK; Wolever TM; Arenovich T; Teo C; Giacca A; Powell V; Clarke L; Fletcher P; Cohn T; McIntyre RS; Gomes S; Chintoh A; Remington GJ
    J Clin Psychopharmacol; 2013 Dec; 33(6):740-6. PubMed ID: 24100786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
    Baptista T; Rangel N; El Fakih Y; Uzcátegui E; Galeazzi T; Beaulieu S; Araujo de Baptista E
    Pharmacopsychiatry; 2009 Jan; 42(1):14-9. PubMed ID: 19153941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.
    Kryzhanovskaya LA; Xu W; Millen BA; Acharya N; Jen KY; Osuntokun O
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):157-65. PubMed ID: 22372514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
    Nachshoni T; Ebert T; Abramovitch Y; Assael-Amir M; Kotler M; Maayan R; Weizman A; Strous RD
    Schizophr Res; 2005 Nov; 79(2-3):251-6. PubMed ID: 16126372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.